Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis

Schramm, Christoph; Wahl, Inka; Weiler‐Normann, Christina; Voigt, Katharina; Wiegard, Christiane; Glaubke, C; Brähler, Elmar; Löwe, Bernd; Lohse, Ansgar W.; Rose, Matthias

doi:10.1016/j.jhep.2013.10.035

Cited by 100 publications

(114 citation statements)

References 33 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…In a single‐centre study, Schramm et al analyzed their cohort of 103 patients with AIH. Using simplified SF‐12 score, they found that mental but not physical component score was impaired in patients with AIH when compared to controls.…”

Section: Discussionmentioning

confidence: 99%

Autoimmune hepatitis exerts a profound, negative effect on health‐related quality of life: A prospective, single‐centre study

Janik

Wunsch

Raszeja‐Wyszomirska

et al. 2018

Liver International

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Autoimmune hepatitis exerts a profound, negative effect on health‐related quality of life: A prospective, single‐centre study

Janik

Wunsch

Raszeja‐Wyszomirska

et al. 2018

Liver International

View full text Add to dashboard Cite

show abstract

“…No association was found between the presence of cirrhosis, the level of ALT, the level of IgG and depressive symptoms, although a correlation was identified between use of prednisolone and the presence of depression. 48 One further question in this area has been whether the fatigue commonly associated with cholestatic liver diseases is a manifestation of depression. In a Dutch cohort of 92 patients with primary biliary cirrhosis or primary sclerosing cholangitis; patients were screened for depressive symptoms through completion of BDI questionnaires, then completed structured psychiatric interviews and were assessed for depression by DSM-IV criteria.…”

Section: Cholestatic and Autoimmune Liver Diseasesmentioning

confidence: 99%

Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation

Mullish

Kabir

Thursz

et al. 2014

Aliment Pharmacol Ther

116

View full text Add to dashboard Cite

SummaryBackgroundThe scale of depression in patients with chronic liver disease (CLD) and those who have received orthotopic liver transplantation (OLT) is poorly characterised. Clinicians are uncertain of how best to manage depression within these patients.AimsTo review the literature evaluating both the prevalence and impact of depression in patients with CLD and post‐OLT, and to assess the safety and efficacy of antidepressant use within this context.MethodsA PubMed search using the phrases ‘chronic liver disease’, ‘cirrhosis’, ‘liver transplantation’, ‘depression’, ‘antidepressant’ and the names of specific causes of liver disease and individual antidepressants.ResultsOver 30% of cirrhotic patients have depressive features, and they experience worse clinical outcomes than nondepressed cirrhotic patients. CLD patients with chronic hepatitis C are particularly prone to depression, partly related to the use of interferon therapy. OLT patients with depression have higher mortality rates than nondepressed patients; appropriate antidepressant use reverses this effect. Selective serotonin reuptake inhibitors (SSRIs) and selective noradrenaline reuptake inhibitors (SNRIs) are effective and generally safe in both CLD and OLT patients.ConclusionsDepression is much more prevalent in CLD or OLT patients than is generally recognised, and it adversely affects clinical outcomes. The reasons for this relationship are complex and multifactorial. Antidepressants are effective in both CLD and post‐OLT, although lower doses or a reduced dosing frequency may be required to minimise side effects, e.g. exacerbation of hepatic encephalopathy. Further research is needed to establish optimal management of depression in these patients, including the potential role of nonpharmacological treatments.

show abstract

“…Maintenance with azathioprine monotherapy where possible is advised in UK and European Guidelines to minimise corticosteroid side effects and their impact on quality of life. The majority of patients require long‐term therapy to prevent relapse and increasing numbers of patients suffer with unpleasant side‐effects, poorly controlled disease and a life‐long immunosuppression burden …”

Section: Introductionmentioning

confidence: 99%

Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom

Dyson

Wong

Bigirumurame

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

There are significant discrepancies in the care received by patients with autoimmune hepatitis in the UK. A high proportion remains on corticosteroids and there is significant treatment variability. Patients receiving care in transplant centres were more likely to achieve and maintain remission. Overall poor remission rates suggest that there are significant unmet therapeutic needs for patients with autoimmune hepatitis.

show abstract

Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis

Cited by 100 publications

References 33 publications

Autoimmune hepatitis exerts a profound, negative effect on health‐related quality of life: A prospective, single‐centre study

Autoimmune hepatitis exerts a profound, negative effect on health‐related quality of life: A prospective, single‐centre study

Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation

Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom

Contact Info

Product

Resources

About